A multicenter, randomized, double-blind, placebo controlled 36 week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant in patients with type 2 diabetes.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

13 May 2019 Trial completed in Finland (End date: 5 Aug 2008).
24 Mar 2012 This trial is recruiting in (Finland) as reported by European Clinical Trials Database record.
26 Sep 2010 Results have been presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com